Human antigen R as a therapeutic target in pathological cardiac hypertrophy

JCI Insight. 2019 Feb 21;4(4):e121541. doi: 10.1172/jci.insight.121541.

Abstract

RNA binding proteins represent an emerging class of proteins with a role in cardiac dysfunction. We show that activation of the RNA binding protein human antigen R (HuR) is increased in the failing human heart. To determine the functional role of HuR in pathological cardiac hypertrophy, we created an inducible cardiomyocyte-specific HuR-deletion mouse and showed that HuR deletion reduces left ventricular hypertrophy, dilation, and fibrosis while preserving cardiac function in a transverse aortic constriction (TAC) model of pressure overload-induced hypertrophy. Assessment of HuR-dependent changes in global gene expression suggests that the mechanistic basis for this protection occurs through a reduction in fibrotic signaling, specifically through a reduction in TGF-β (Tgfb) expression. Finally, pharmacological inhibition of HuR at a clinically relevant time point following the initial development of pathological hypertrophy after TAC also yielded a significant reduction in pathological progression, as marked by a reduction in hypertrophy, dilation, and fibrosis and preserved function. In summary, this study demonstrates a functional role for HuR in the progression of pressure overload-induced cardiac hypertrophy and establishes HuR inhibition as a viable therapeutic approach for pathological cardiac hypertrophy and heart failure.

Keywords: Cardiology; Cardiovascular disease; Cell Biology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiotonic Agents / pharmacology
  • Cardiotonic Agents / therapeutic use
  • Disease Models, Animal
  • ELAV-Like Protein 1 / antagonists & inhibitors
  • ELAV-Like Protein 1 / genetics
  • ELAV-Like Protein 1 / metabolism*
  • Fibrosis
  • Heart Failure / drug therapy
  • Heart Failure / pathology*
  • Heart Ventricles / cytology
  • Heart Ventricles / drug effects
  • Heart Ventricles / pathology
  • Humans
  • Hypertrophy, Left Ventricular / drug therapy*
  • Hypertrophy, Left Ventricular / genetics
  • Hypertrophy, Left Ventricular / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myocardium / cytology
  • Myocardium / pathology*
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • RNA-Seq
  • Ventricular Remodeling / drug effects

Substances

  • Cardiotonic Agents
  • ELAV-Like Protein 1
  • ELAVL1 protein, human
  • Elavl1 protein, mouse